Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Assets (2018 - 2026)

10x Genomics' Other Non-Current Assets history spans 8 years, with the latest figure at $2.9 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 29.45% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 29.45% decrease, with the full-year FY2025 number at $2.9 million, down 29.45% from a year prior.
  • Other Non-Current Assets hit $2.9 million in Q4 2025 for 10x Genomics, up from $1.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for TXG hit a ceiling of $61.0 million in Q4 2023 and a floor of $1.9 million in Q3 2025.
  • Historically, Other Non-Current Assets has averaged $9.1 million across 5 years, with a median of $4.9 million in 2024.
  • The widest YoY moves for Other Non-Current Assets: up 64.86% in 2024, down 93.23% in 2024.
  • Tracing TXG's Other Non-Current Assets over 5 years: stood at $8.6 million in 2021, then dropped by 17.8% to $7.1 million in 2022, then skyrocketed by 759.96% to $61.0 million in 2023, then plummeted by 93.23% to $4.1 million in 2024, then decreased by 29.45% to $2.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for TXG at $2.9 million in Q4 2025, $1.9 million in Q3 2025, and $2.7 million in Q2 2025.